Genpact announced today that it teamed up with Embecta (Nasdaq:EMBC) to support the company in the diabetes technology market.
The company says it has been working with Embecta to support its spinoff from BD and subsequent evolution as a company.
“From the beginning, our relationship was rooted in shared values and a commitment to mutual success,” Devdatt (Dev) Kurdikar, president and CEO, Embecta, said in a news release. “Our seamless collaboration resulted in the successful transition of embecta to an independent entity, ensuring a continuous flow of goods and working capital, maintaining supply chain continuity, and providing critical support for our customers and the people they serve.”
Genpact said it initially supported the spin in 2022, then over time the two companies established a partnership. They aim to modernize Embecta’s operations.
Specifically, Genpact supported the implementation of an ERP and launched an operating model with standardized global processes. It said these helped Embecta meet the needs of a newly formed medical device company. It also established end-to-end HR, finance and procurement processes. This helped provide customer support and supply chain stability for Embecta to continue providing insulin injection devices around the world.
“Genpact’s deep expertise in the life sciences and healthcare sectors enables us to leverage extensive knowledge alongside our capabilities in data, technology, and AI. This combination allows us to drive positive outcomes and provide innovative solutions tailored to our clients’ needs,” said Balkrishan “BK” Kalra, president and CEO, Genpact.
This is an interesting time for Embecta, which could be in line for a massive shake-up. Financial Times reported recently that the former BD diabetes unit hired advisers to look into a possible sale of the company. The outlet said private equity, in particular, could be an area of interest with a potential sale on the horizon.
